Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28212451 | 1.00 | TSHR (0.46) | TSHRCA12CA14GAAHSD17B10 | |
| SCHEMBL1123070 | 0.97 | — | — | |
| SCHEMBL29889907 | 0.95 | TSHR (0.46) | TSHRCA12CA14GAAHSD17B10 | |
| SCHEMBL8375840 | 0.95 | TSHR (0.46) | TSHRCA12CA14GAAHSD17B10 | |
| SCHEMBL18775983 | 0.81 | TSHR (0.39) | TSHRCA12CA14GAAHSD17B10 | |
| SCHEMBL10622350 | 0.78 | TSHR (0.52) | TSHRCA12CA14GAAHSD17B10 | |
| SCHEMBL18935633 | 0.76 | — | — | |
| SCHEMBL1968530 | 0.76 | — | — | |
| Dimethyl Succinate SCHEMBL27988577 | 0.76 | TSHR (0.72) | TSHRCA12CA14GAAHSD17B10 | |
| SCHEMBL7009464 | 0.75 | GAA (0.50) | CA12GAAHSD17B10MGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007143672-A1 | COMPOSITION COMPRISING JOJOBA CARBOXYLATES IN COMBINATION WITH JOJOBA ALCOHOLS, AND PERSONAL CARE FORMULATIONS COMPRISING SAME | DESERT WHALE JOJOBA COMPANY, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070286839-A1 | COMPOSITION COMPRISING JOJOBA CARBOXYLATES IN COMBINATION WITH JOJOBA ALCOHOL AND COSMETIC FORMULATION COMPRISING SAME | ROHDE SORAYA | 2007-12-13 | — | — | US | disclosed |
| US-4283416-A | Fungicidal, miticidal and ovicidal alkoxycarbonylalkyl-substituted and carbamylalkyl-substituted N-haloalkylthiosulfonamides | CHEVRON RESEARCH COMPANY (US) | 1981-08-11 | — | — | US | disclosed |
| US-4230875-A | Fungicidal, miticidal and ovicidal alkoxycarbonylalkyl-substituted and carbamylalkyl-substituted N-haloalkylthiosulfonamides | CHEVRON RESEARCH COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4112237-A | Fungicidal, miticidal and ovicidal alkoxycarbonylalkyl-substituted and carbamylalkyl-substituted N-haloalkylthiosulfonamides | CHEVRON RESEARCH COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070286839-A1 | COMPOSITION COMPRISING JOJOBA CARBOXYLATES IN COMBINATION WITH JOJOBA ALCOHOL AND COSMETIC FORMULATION COMPRISING SAME | CUTA, TP53RK, POLB | TSHR 2299/4885CA12 1935/4885CA14 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.